- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01597154
Lifestyle Therapy for Youth With Type 2 Diabetes (BDT)
Beating Diabetes Together: A Randomized Controlled Trial for Intensive Lifestyle Therapy for Youth With Type 2 Diabetes
Background: Little is known about the efficacy of intensive lifestyle therapy (i.e. increased physical activity and dietary changes) for the management of glycemia and cardiometabolic risk factors in children and adolescents with type 2 diabetes (T2DM).
Our hypothesis is that education regarding healthy lifestyle changes will significantly reduce blood sugars in youth with T2DM that do not require insulin therapy. Our secondary hypothesis is that the intensive lifestyle therapy will cause quick and sustained reductions in health risk measured by body mass index (BMI), blood pressure, waist circumference, LDL cholesterol, serum triglycerides and apolipoprotein B.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0P4
- Manitoba Institute of Child Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- youth with a BMI considered overweight according to the International Obesity Task Force
- diagnosed with type 2 diabetes, confirmed with a 2-hour oral glucose tolerance test within two years of enrollment
Exclusion Criteria:
- youth with type 1 diabetes
- use of insulin or other anti-diabetic drugs
- youth with medication-induced diabetes
- youth who have recently been admitted to hospital with ketoacidosis
- youth have experienced weight loss or enrolled in a weightloss program in the last 6 months
- youth with an orthapaedic injury preventing them from exercising
- youth who have a history of alcohol or drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lifestyle counselling
Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
|
Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
|
No Intervention: Control
Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glycemic control determined by a standard fasting measure of glycosylated hemoglobin using internationally recognized DCCT assay
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiometabolic risk Z score
Time Frame: 16 weeks
|
This is a composite score based on BMI z-score, waist circumference, c-reactive protein (CRP), fibrinogen, low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol, triglycerides (TG) and apolipoprotein B (apoB), and a marker of fatty liver disease, alanine transaminase (ALT)
|
16 weeks
|
Presence of microalbuminuria
Time Frame: 16 weeks
|
defined as a first morning albumin:creatinine ratio (ACR) 2.5-25 mg/mmol in a first morning urine collection
|
16 weeks
|
Hypertension
Time Frame: 16 weeks
|
defined as a systolic blood pressure load >25% or a mean 24 hour systolic blood pressure >95th %ile for sex and height on 24 hour ambulatory blood pressure monitoring
|
16 weeks
|
Anthropometrics
Time Frame: 16 weeks
|
Waist circumference in centimeters, body mass index (BMI) z-score and percent body fat will be assessed to determine if changes in body composition are associated with improvements in cardiometabolic risk
|
16 weeks
|
Cardiovascular structure and function
Time Frame: 16 weeks
|
Vascular health will be assessed with non-invasive assessments of arterial stiffness, endothelium-dependant relaxation and carotid intima media thickness which will be treated as continuous variables.
Left ventricular structure and function will be assessed using standard M-mode and doppler ultrasound techniques
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathon McGavock, PhD, University of Manitoba
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2012:023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Lifestyle Counselling
-
University of AlbertaDanone Institute InternationalCompleted
-
University of PlymouthCompleted
-
NHS GrampianCompleted
-
Kigali University Teaching HospitalSanofiCompletedDiabetes MellitusRwanda
-
Istituto Auxologico ItalianoActive, not recruitingAtrial Fibrillation | Osa SyndromeItaly
-
Finnish Institute for Health and WelfareUniversity of Eastern Finland; University of Oulu; Finnish Diabetes AssociationActive, not recruiting
-
Marie-France LangloisThe Lawson FoundationCompletedObesity | Glucose IntoleranceCanada
-
University of TromsoUniversity Hospital of North NorwayCompleted
-
Harokopio UniversityThe University of Texas Medical Branch, GalvestonCompleted
-
Henner HanssenUniversitaire Ziekenhuizen KU Leuven; University Hospital, Basel, SwitzerlandRecruitingGlaucoma, Open-Angle | Exercise Training | Microvascular HealthSwitzerland